Biochemistry · 2018 · 57 citations · 15 references
Life SciencesMolecular BiologyNeuroscienceMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationAmyloid FormationNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseProtein AggregationProtein Aggregation DisordersAggregationAggregation PropensityAlpha-synuclein AggregationAlpha-synuclein MisfoldingAmyloid Aggregation KineticsAmyloid Fibril FormationAmyloid Oligomer FormationOligomerization
The involvement of α-synuclein (α-Syn) amyloid formation in Parkinson's disease (PD) pathogenesis is supported by the discovery of α-Syn gene (SNCA) mutations linked with familial PD, which are known to modulate the oligomerization and aggregation of α-Syn. Recently, the A53V mutation has been discovered, which leads to late-onset PD. In this study, we characterized for the first time the biophysical properties of A53V, including the aggregation propensities, toxicity of aggregated species, and membrane binding capability, along with those of all familial mutations at the A53 position. Our data suggest that the A53V mutation accelerates fibrillation of α-Syn without affecting the overall morphology or cytotoxicity of fibrils compared to those of the wild-type (WT) protein. The aggregation propensity for A53 mutants is found to decrease in the following order: A53T > A53V > WT > A53E. In addition, a time course aggregation study reveals that the A53V mutant promotes early oligomerization similar to the case for the A53T mutation. It promotes the largest amount of oligomer formation immediately after dissolution, which is cytotoxic. Although in the presence of membrane-mimicking environments, the A53V mutation showed an extent of helix induction capacity similar to that of the WT protein, it exhibited less binding to lipid vesicles. The nuclear magnetic resonance study revealed unique chemical shift perturbations caused by the A53V mutation compared to those caused by other mutations at the A53 site. This study might help to establish the disease-causing mechanism of A53V in PD pathology.
15
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
Rakez Kayed, Elizabeth Head, Jennifer L. Thompson et al. · Science · 2003 · 4.1K citations
Kelly A. Conway, Seung‐Jae Lee, Jean‐Christophe Rochet et al. · Proceedings of the National Academy of Sciences · 2000 · 1.5K citations
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner, Roberto Jappelli, Samir K. Maji et al. · Proceedings of the National Academy of Sciences · 2011 · 1.5K citations · Full text